ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
80 hedge funds and large institutions have $976M invested in ESSA Pharma in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
14% more funds holding
Funds holding: 70 → 80 (+10)
9% more capital invested
Capital invested by funds: $896M → $976M (+$80.3M)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6.86% less ownership
Funds ownership: 91.28% → 84.42% (-6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$80.5M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$18.4M |
| 3 |
Janus Henderson Group
London,
|
+$14.6M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$8.74M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$8.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$15M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$13.3M |
| 3 |
Blackstone Inc
New York
|
-$7.85M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$7.69M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.89M |
EPIX Hedge Fund Activity: Q2 2021 in Review
80 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2021, worth a combined $976M — up 9% from $896M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new EPIX positions and 8 closed out — a net gain of 10 holders — while 23 added to existing stakes and 21 trimmed.
The largest buyer was RTW Investments, adding an estimated $80.5M. The largest seller was Vivo Capital, cutting an estimated $15M.
- 80 institutional investors held ESSA Pharma (EPIX) as of Q2 2021, up from 70 in Q1 2021.
- Funds reported $976M of ESSA Pharma stock for Q2 2021, up 9% quarter-over-quarter.
- 18 funds opened new ESSA Pharma positions in Q2 2021 and 8 closed out, a net change of +10 holders.
- The largest ESSA Pharma buyer in Q2 2021 was RTW Investments, an estimated $80.5M added.
- The largest ESSA Pharma seller in Q2 2021 was Vivo Capital, an estimated $15M sold.
Based on aggregated 13F filings for Q2 2021.